Education
About Us
Working with TipRanks
Follow Us
Terns Pharmaceuticals, Inc. (TERN)
NASDAQ:TERN
TERN Stock Chart & Stats
$34.26
-$0.29(-5.06%)
At close: 4:00 PM EST
$34.26
-$0.29(-5.06%)
Day’s Range― - ―
52-Week Range$1.87 - $48.26
Previous CloseN/A
Volume294.76K
Average Volume (3M)2.07M
Market Cap
$3.64B
Enterprise Value$2.93B
Total Cash (Recent Filing)$295.63M
Total Debt (Recent Filing)$1.03M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Mar 31, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding106,329,780
10 Day Avg. Volume1,595,522
30 Day Avg. Volume2,065,327
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)1.27
Price to Sales (P/S)0.00
P/FCF Ratio-6.29
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-27.14K
Enterprise Value/Ebitda-28.88
Forecast
1Y Price Target
$53.75Price Target Upside56.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.18
Revenue Forecast (FY)$960.00K
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyEarly clinical results show strong and durable molecular responses, including benefit in patients previously treated with asciminib, supporting TERN-701's potential to outperform existing therapies.
Financial RunwayA multi-year cash runway materially de-risks development and supports advancement toward pivotal studies without immediate financing pressure.
Safety And TolerabilityReported safety profile shows no pancreatic, hypertension, or cardiovascular toxicities and mostly low-grade events, indicating a tolerable profile that could support broader use.
Bears Say
Investor Outcome RiskPersistent regulatory uncertainty raises binary outcome risk that may drive higher share-price volatility if pivotal trial starts are postponed or new requirements emerge.
Regulatory Guidance UncertaintyLack of definitive end-of-phase-2 guidance could require more complex trial designs or additional data, increasing development costs and extending timelines.
Regulatory Timing RiskUnresolved regulatory interactions and an outstanding end-of-phase-2 meeting create the risk of delayed initiation of pivotal trials, which could push back key value inflection points.
Terns Pharmaceuticals News
TERN FAQ
What was Terns Pharmaceuticals, Inc.’s price range in the past 12 months?
Terns Pharmaceuticals, Inc. lowest stock price was $1.86 and its highest was $48.26 in the past 12 months.
What is Terns Pharmaceuticals, Inc.’s market cap?
Terns Pharmaceuticals, Inc.’s market cap is $3.64B.
When is Terns Pharmaceuticals, Inc.’s upcoming earnings report date?
Terns Pharmaceuticals, Inc.’s upcoming earnings report date is Mar 31, 2026 which is in 60 days.
How were Terns Pharmaceuticals, Inc.’s earnings last quarter?
Terns Pharmaceuticals, Inc. released its earnings results on Nov 10, 2025. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.294 by $0.024.
Is Terns Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Terns Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Terns Pharmaceuticals, Inc. pay dividends?
Terns Pharmaceuticals, Inc. does not currently pay dividends.
What is Terns Pharmaceuticals, Inc.’s EPS estimate?
Terns Pharmaceuticals, Inc.’s EPS estimate is -0.3.
How many shares outstanding does Terns Pharmaceuticals, Inc. have?
Terns Pharmaceuticals, Inc. has 106,329,780 shares outstanding.
What happened to Terns Pharmaceuticals, Inc.’s price movement after its last earnings report?
Terns Pharmaceuticals, Inc. reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.294. Following the earnings report the stock price went up 7.636%.
Which hedge fund is a major shareholder of Terns Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in TERN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Terns Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.75 (56.89% Upside)
$53.75 (56.89% Upside)
Blogger Sentiment
Bullish
TERN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 65.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $44.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.9%
Last 30 Days ▲ 18.0%
Last 30 Days ▲ 18.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
718.18%
12-Months-Change
Fundamentals
Return on Equity
-29.12%
Trailing 12-Months
Asset Growth
-20.25%
Trailing 12-Months
Company Description
Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
TERN Stock 12 Month Forecast
Average Price Target
$53.75
▲(56.89% Upside)
Technical Analysis
AnaptysBio
―
Keros Therapeutics
―
Nurix Therapeutics
―
Olema Pharmaceuticals
―
Tyra Bioscience
―
Ownership Overview
0.66% Insiders
8.26% Mutual Funds
0.02% Other Institutional Investors
81.62% Public Companies and
Individual Investors